Register Now: Image-Based Risk: The Next Frontier in Breast Cancer Screening
|Articles|August 28, 1996

Cytogen signs deal with C.R. Bard

Cytogen of Princeton, NJ, has inked a 10-year co-marketing dealwith C.R. Bard of Murray Hill, NJ, for sales of Cytogen's ProstaScintmonoclonal antibody-based agent for detecting prostate cancer.A Food and Drug Administration advisory committee

Cytogen of Princeton, NJ, has inked a 10-year co-marketing dealwith C.R. Bard of Murray Hill, NJ, for sales of Cytogen's ProstaScintmonoclonal antibody-based agent for detecting prostate cancer.A Food and Drug Administration advisory committee recommendedProstaScint for approval last month (SCAN 7/31/96).

Under terms of the deal, C.R. Bard's Bard Urological divisionwill market ProstaScint to office and hospital-based urologists.The product should be a useful adjunct to a tumor assessment serviceunder development at the division to help in staging prostatecancer.

Cytogen will sell ProstaScint to the medical imaging marketand will handle ongoing clinical trials, manufacturing, distribution,and FDA activities related to ProstaScint's product license application.

Cytogen last month released financial results for its secondquarter (end-June) that showed revenues doubling and the company'snet loss narrowing. For the quarter, Cytogen had revenues of $1.6million, compared with $812,000 for the second quarter of 1995.Most of the increase was due to license and contract revenue:Revenues from sales of Cytogen's OncoScint CR/OV product increasedonly slightly, to $359,000 from $354,000 in the same period lastyear. Cytogen's net loss was $5.3 million, compared with a netloss of $6.3 million in the second quarter of 1995.

Related to this article

Teleradiology With More Pay and Less Pressure
Expert Radiology is a **radiologist-run teleradiology practice with 10 years of experience**, hiring teleradiologists earning **$500–$900/hr with per-dictation pay**. Work from anywhere with true flexibility, **no shifts, no call, and no weekends**. Our case mix is **predominantly outpatient and noncontrast**, with approximately **75% MRI**, plus X-ray and CT. We cover **malpractice with tail**, handle all medical licensing, and ship you a **$10K reading station with six vertical 4K monitors**. Minimum commitment is an **average of 400 cases per month**. **Book a call with Brandi Escapule, Principal, Physician Services.**
Key Sessions of Interest for Radiologists at the Upcoming HLTH USA Conference
How will generative AI software be evaluated by the FDA in the future? What’s next for point-of-care ultrasound? What steps have been successful in facilitating adoption of AI applications across enterprise systems? Leaders in radiology and health care will be discussing these topics and more at the upcoming HLTH USA conference.